Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929044 | 0.84 | PDE2A (0.35) | CYP1A2CYP2D6ALDH1A1CA2CA4 | |
| SCHEMBL9928957 | 0.82 | LMNA (0.37) | LMNATP53HTTCYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL9929353 | 0.81 | LMNA (0.36) | LMNATP53HTTCYP1A2CYP3A4 | |
| SCHEMBL9929288 | 0.77 | ACLY (0.33) | — | |
| SCHEMBL9952480 | 0.75 | PDE2A (0.33) | CA2CA4 | |
| SCHEMBL22646842 | 0.75 | LMNA (0.39) | LMNATP53HTTCYP1A2CYP3A4 | |
| SCHEMBL1747991 | 0.75 | LMNA (0.39) | LMNATP53HTTCYP1A2CYP3A4 | |
| SCHEMBL9928940 | 0.71 | LMNA (0.39) | LMNATP53HTTCA2CA4 | |
| SCHEMBL20681148 | 0.70 | LMNA (0.36) | LMNA | |
| SCHEMBL12813061 | 0.70 | LMNA (0.38) | LMNATP53HTTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3660016-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-2655374-B1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2019-10-23 | — | — | EP | disclosed |
| US-9815839-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170158696-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-06-08 | — | — | US | disclosed |
| US-9527848-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-9126948-B2 | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126948-B2 | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9126948-B2 | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-9096600-B2 | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors | INCYTE CORPORATION (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2655374-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | Incyte Corporation (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012135009-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012135009-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012087881-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157430-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | LMNA 3738/4885TP53 977/4885HTT 2166/4885 |
| US-20150284390-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | LMNA 3738/4885TP53 977/4885HTT 2166/4885 |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | LMNA 4837/4885TP53 1246/4885HTT 4568/4885 |
| US-20170158696-A1 | N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PI4KB | LMNA 3738/4885TP53 977/4885HTT 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.